The long-held assumption that the brain is immunologically isolated has been quietly dismantled over the past decade — but a new synthesis now points to something even more architecturally precise: the skull itself may function as a first-responder immune organ during stroke, with direct anatomical highways into the brain's border compartments.
This review in Experimental Neurology consolidates emerging evidence for what researchers describe as a skull bone marrow-meninges-brain axis. Vascular channels perforating the calvaria — the dome of the skull — create direct conduits linking cranial bone marrow with the dura mater. Following ischemic stroke, brain-derived inflammatory signals appear to activate these adjacent marrow niches, prompting the migration of myeloid immune cells toward meningeal spaces. Simultaneously, meningeal lymphatic vessels — themselves only described in humans around 2015 — serve as the efflux arm of this system, clearing cerebrospinal fluid-borne inflammatory mediators, antigens, and cellular debris toward deep cervical lymph nodes. The review frames these dynamics within a stage-dependent influx-efflux model: early post-ischemic hours favor cellular influx through skull-dura channels, while lymphatic efflux governs later resolution and antigen clearance.
This axis framework represents a meaningful conceptual advance. Prior stroke immunology focused primarily on circulating leukocytes crossing the disrupted blood-brain barrier from systemic blood — a longer, more diffuse route. The calvarial channel pathway is spatially proximate, potentially faster, and anatomically privileged, suggesting the skull marrow could prime or amplify neuroinflammation before peripheral immune cells even arrive in significant numbers. Critically, this is a review rather than an original trial, so causal claims remain provisional. Most direct mechanistic evidence derives from rodent models, and whether calvarial channels operate at comparable scale in humans remains to be confirmed. Still, as a conceptual scaffold, this axis has real implications: meningeal lymphatic enhancement is already being explored as a therapeutic target in Alzheimer's disease, and the stroke context adds urgency to that line of inquiry.